# 中华人民共和国生物安全法 (Biosafety Law of the People's Republic of China)

- **Source**: exportcontrol.mofcom.gov.cn
- **URL**: http://exportcontrol.mofcom.gov.cn/article/zcfg/gnzcfg/flfg/202111/228.html
- **Date**: 2021-12-30
- **Category**: regulation_update
- **Fetched**: 2026-02-13
- **Confidence**: 高

## Summary

The Biosafety Law of the PRC establishes a comprehensive framework for national biosafety governance, covering infectious disease prevention, biotechnology research safety, pathogenic laboratory management, human genetic resources protection, and bioterrorism prevention. Adopted on October 17, 2020, and effective from April 15, 2021, this law creates mandatory risk assessment and classification systems with penalties ranging from warnings to criminal prosecution.

## Key Details

- **Issuing Authority**: Standing Committee of the National People's Congress (全国人民代表大会常务委员会)
- **Effective Date**: 2021-04-15
- **Scope**: All entities and individuals engaged in biological research, development, production, storage, transport, use, disposal activities within PRC territory; includes foreign genetic resource collection, laboratory operations, dual-use biotechnology research, and cross-border biological material transfer

## Key Provisions

### Chapter I: General Provisions (Articles 1-9)
- Defines biosafety as "a state where the nation effectively prevents biological threats" while maintaining ecosystem stability
- Establishes state biosafety coordination mechanism and expert committee system
- Mandates risk assessment for all biological activities

### Chapter II: Biosafety Risk Prevention System (Articles 10-26)
- Creates national biosafety monitoring and early warning systems
- Requires information sharing protocols across government departments
- Establishes inspection authority and emergency response mechanisms
- Mandates risk classification for biological activities

### Chapter III: Major Infectious Disease Control (Articles 27-33)
- Requires comprehensive disease surveillance networks for humans and animals
- Establishes mandatory reporting requirements for infectious disease outbreaks
- Creates prevention mechanisms and emergency response protocols

### Chapter IV: Biotechnology Research Safety (Articles 34-41)
- Classifies biotechnology research into three risk categories:
  - High risk: Requires national-level approval and oversight
  - Medium risk: Provincial approval with strict monitoring
  - Low risk: Institution-level approval with basic compliance
- Mandates risk assessment before research commencement
- Establishes equipment and material traceability systems
- Prohibits illegal gene editing and human cloning research

### Chapter V: Pathogenic Microorganism Laboratory Safety (Articles 42-52)
- Implements four-tier laboratory classification system (BSL-1 through BSL-4)
- Requires laboratory certification and periodic inspection
- Mandates strict access controls and personnel training
- Establishes waste management and decontamination protocols
- Requires approval for high-risk pathogen storage and transfer

### Chapter VI: Human Genetic & Biological Resources (Articles 53-60)
- Protects national sovereignty over genetic resources
- Requires government approval for:
  - Collection of human genetic resources by foreign entities
  - Export or transfer of genetic materials abroad
  - International collaborative research involving Chinese genetic resources
- Prohibits introduction of invasive species
- Establishes benefit-sharing mechanisms for genetic resource utilization

### Chapter VII: Bioterrorism & Bioweapon Prevention (Articles 61-65)
- Explicitly prohibits development, production, stockpiling, and use of biological weapons
- Establishes monitoring mechanisms for dual-use biological agents and technologies
- Requires export control compliance for precursor materials
- Mandates suspicious activity reporting

### Chapter VIII: Biosafety Capacity Building (Articles 66-71)
- Requires infrastructure development for biosafety systems
- Mandates scientific research support and funding
- Establishes personnel protection mechanisms
- Promotes public education and international cooperation

### Chapter IX: Legal Liability (Articles 72-84)
Penalties by violation type:
- **Unauthorized high-risk research**: RMB 1-10 million fine, potential criminal prosecution
- **Laboratory violations**: RMB 50,000-5 million fine, facility closure
- **Illegal genetic resource export**: RMB 1-10 million fine, confiscation of materials
- **Bioterrorism activities**: Criminal prosecution under Criminal Law
- **Government official negligence**: Administrative sanctions, potential criminal liability

### Chapter X: Supplementary Provisions (Articles 85-88)
Defines 11 key terms including:
- **Biosafety**: State where nation prevents biological threats effectively
- **Emerging infectious disease**: Newly identified or re-emerging disease with public health significance
- **Dual-use biological agents**: Materials with both legitimate and potential harmful applications
- **Bioweapon**: Biological agents intended to cause disease or death

## Supply Chain Impact Assessment

*The following assessment is speculative analysis based on regulatory provisions:*

**Export Control Implications:**
- The law's dual-use biotechnology provisions (Chapter IV & VII) directly intersect with export control requirements, as certain biological materials, equipment, and technologies now require both biosafety approval AND export licensing
- Foreign companies sourcing biological materials or genetic resources from China must obtain multiple approvals, potentially extending lead times by 3-12 months

**Laboratory Equipment & Reagent Trade:**
- BSL-3 and BSL-4 laboratory equipment suppliers must now verify end-user compliance with Chinese biosafety certification before export to China
- Pathogenic microorganism cultures and diagnostic reagents face enhanced scrutiny under the traceability system (Article 38)

**Pharmaceutical & Biotech R&D:**
- International collaborative research involving Chinese human genetic resources requires government approval (Article 56), affecting clinical trial timelines
- Genetic resource benefit-sharing requirements may impact licensing agreements and royalty structures

**Agricultural Biotechnology:**
- Invasive species provisions (Article 60) affect agricultural biotech product introductions, requiring biosafety assessments before market entry
- Gene-edited crop and livestock imports face additional regulatory hurdles

**Risk Mitigation Strategies:**
- Establish early dialogue with MOFCOM and Ministry of Ecology for dual-use material exports
- Budget 6-12 month lead time for genetic resource collection approvals
- Implement internal biosafety compliance systems aligned with PRC standards
- Consider localization of certain biological research activities within China to avoid cross-border transfer restrictions

**Timeline Sensitivity:**
- Law took effect April 15, 2021, with transitional periods for existing facilities and research projects
- Non-compliant activities after effective date subject to full penalties
- Foreign entities with pre-existing genetic resource collection agreements required to re-register within 12 months

## Notes

- Full legislative text retrieved successfully via WebFetch
- Law comprises 10 chapters with 88 articles
- This law complements existing export control regulations under the PRC Export Control Law (2020) and Biosecurity regulations
- Cross-references Criminal Law for bioterrorism prosecution
- Implementing regulations and technical standards issued by State Council and relevant ministries
- Disclaimer: This analysis is for informational purposes only and does not constitute legal advice. Entities affected by this law should consult qualified legal counsel in China.

---

*Source: China Ministry of Commerce Export Control Information Network*
